Menu
Recruiting NCT06178822

Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room

Observational Sepsis Septic Shock Sepsis, Severe Infections

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: No intervention.
Who it may be relevant to
Registry conditions: Sepsis, Septic Shock, Sepsis, Severe, Infections. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Netherlands
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Objectives: 1. To compare the immune response of patients with or without sepsis presenting to the ED with a(n) (suspected) infection. 2. To determine immune response aberrations that are associated with an increased risk of developing sepsis in patients presenting to the ED with a(n) (suspected) infection without sepsis. 3. To determine the long term cognitive and physical sequelae of sepsis after admission.

Detailed description

Sepsis will be defined in accordance with the current Sepsis 3.0 criteria as a(n) (suspected) infection with evidence of organ failure, as reflected by a SOFA (Sequential Organ Failure Assessment) score of ≥2. Notably, a molecular definition of sepsis does not exist and there is no pathological gold standard; therefore, in accordance with the current international consensus, the investigators consider the commonly used clinical organ failure (SOFA) criteria as the best option. The SOFA score is composed of six organ dysfunctions (cardiovascular, pulmonary, renal, hepatic, coagulation and neurological). The SOFA score was developed for ICU patients, but its components can be easily scored in an ED (and hospital ward) setting with the exception of the pulmonary component; this pulmonary dysfunction score is based on the PaO2/FiO2 (PF) ratio, wherein PaO2 is the partial pressure of oxygen in arterial blood and FiO2 the fraction of inspired oxygen. Measurement of the PaO2 requires an arterial blood puncture, which is not routinely done on the ER or hospital ward. Therefore, the investigators will use an alternative method to determine the respiratory SOFA by determining the SpO2/FiO2 (SF) ratio, wherein SpO2 is peripheral oxygen saturation. SpO2 is routinely measured by finger pulse oximeter in patients with suspected infection; FiO2 is 21% when breathing room temperature and increases by 4% with each liter of oxygen provided per minute to a patient via a nasal cannula. Cut-off values for SF ratios correlating with SOFA pulmonary scores based on PF ratios have been validated in large data sets.

Interventions

  • Other No intervention
    There is no intervention

Primary outcome measures

  • Final diagnosis for hospitalization [Time frame: 4 years]
  • Disease severity [Time frame: During hospitalization (up to day 180)]
  • Mortality [Time frame: 4 years]
Secondary outcome measures (4)
  • Length of stay [Time frame: During hospitalization (up to day 180)]
  • Mortality [Time frame: 5 years]
  • Post-sepsis sequelae [Time frame: Up to 1 year after sepsis episode]
  • Readmissions [Time frame: 5 years]

Eligibility criteria

Inclusion criteria

  • Age 18 years or higher
  • Presentation at the Emergency Department (ED)
  • Clinical suspicion of infection or earlier confirmed infection
  • Modified Early Warning Score (MEWS) of 2 or higher

Exclusion criteria

  • No informed consent given

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Netherlands · 3 centers
  • Flevoziekenhuis — Almere Stad
  • Amsterdam UMC, location VUMC — Amsterdam
  • Amsterdam UMC, location AMC — Amsterdam

Publications

  • Reijnders E, Turgman O, Joosten SCM, Schinkel M, Slim MA, Douma RA, Moeniralam HS, Peters-Sengers H, van der Poll T, Wiersinga WJ. Towards novel BIOmarkers to diagnose SEPsis (BIOSEP) in the emergency room: a protocol for a multicentre, prospective cohort study. BMJ Open. 2025 Aug 1;15(7):e103138. doi: 10.1136/bmjopen-2025-103138. PMID 40750284

Identifiers

NCT: NCT06178822 · BIOSEP

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗